Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients

This study is currently recruiting participants.
Verified January 2013 by Tel-Aviv Sourasky Medical Center
Sponsor:
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01781754
First received: January 8, 2013
Last updated: January 30, 2013
Last verified: January 2013

January 8, 2013
January 30, 2013
January 2013
January 2014   (final data collection date for primary outcome measure)
Levels of gene expression for UCP2 (RQ) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Checking UCP2 levels compared to HgBA1c
Same as current
Complete list of historical versions of study NCT01781754 on ClinicalTrials.gov Archive Site
Improved metabolic state [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Glycemic control (glucose level and HgA1c), levels of free reactive oxygen species (ROS) and non-esterified fatty acids (NEFAs).
Same as current
Not Provided
Not Provided
 
Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients
Changes in UCP2 mRNA in T2DM Patients

Many patients with Diabetes find difficulties in achieving glycemic control. Hemoglobin A1c(HgBA1c) is used as a marker for glycemic control. UCP2 is affected by high glucose levels, high free fatty acids and high oxidative stress.

The investigators intend to learn about the changes in UCP2 along the process of reaching glycemic control.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Whole blood for UCP2 mRNA

Non-Probability Sample

Un balanced diabetic patients

Diabetes
Procedure: Blood withdrawal
This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
Diabetic patients
Un balanced diabetic patients
Intervention: Procedure: Blood withdrawal

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Un balanced diabetic patients.

Exclusion Criteria:

  • No current infection.
Both
20 Years to 75 Years
No
Contact: Nachum Vaisman, MD 972-3-6974807 vaisman@tasmc.health.gov.il
Israel
 
NCT01781754
TASMC-11-NV-561-CTIL
No
Tel-Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
Not Provided
Not Provided
Tel-Aviv Sourasky Medical Center
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP